# US 2026/0062482 A1 · Anti-unc5c antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062482 A1
- Document ID: US20260062482A1
- Status: Published application
- Kind: A1
- Application number: 19/264,764
- Filed: 2025-07-09
- Published: 2026-03-05
- Earliest claimed: 2024-07-10
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Iosif Pediaditakis; Michelle Sidor; James McCarthy; Sandrine Legg; Giles Lewis; Laura Sophie Mitchell; Justin Barton; Emma Louise Jenkins Knight; Ralph Raymond Minter; Donna Finch; Jacob Daniel Galson; Jane Katharine Osbourn; Jorge Norman Dias Do Nascimento; Paulina Maria Kolasinska-Zwierz; William James Hawthorne
- Web page: https://patentgrep.com/patent/US20260062482A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies that bind UNC5C and fragments thereof are described. Compositions comprising these antibodies, as well as methods, including therapeutic methods and therapeutic uses of the antibodies are also described.

## Claims

### Claim at position 1

-35. (canceled)

### Claim 36

An isolated antibody or an antigen binding fragment thereof, wherein the antibody comprises a heavy chain variable region comprising a heavy chain complementarity determining region (CDRH) 1 comprising GGSISSYF (SEQ ID NO: 20), a CDRH2 comprising IHYSGTT (SEQ ID NO: 22), a CDRH3 comprising ARGRGMATLPFDY (SEQ ID NO: 23) and a light chain variable region comprising a light chain complementarity determining region (CDRL) 1 comprising QSISSY (SEQ ID NO: 24), a CDRL2 comprising AAS (SEQ ID NO: 34), and a CDRL3 comprising QQSYSTPLT (SEQ ID NO: 40).

### Claim 37

The isolated antibody or antigen binding fragment thereof, wherein the antibody specifically binds human UNC5C.

### Claim 38 (depends on 36)

The isolated antibody or antigen binding fragment thereof of claim 36, wherein the antibody does not detectably bind human UNC5A, UNC5B, UNC5D, DCC, and/or neogenin-1).

### Claim 39 (depends on 36)

A nucleic acid or a set of nucleic acids comprising a nucleotide sequence encoding the isolated antibody of claim 36.

### Claim 40 (depends on 39)

A vector or set of vectors comprising the nucleic acid or set of nucleic acids of claim 39.

### Claim 44 (depends on 40)

A host cell comprising the vector or set of vectors of claim 40.

### Claim 45 (depends on 36)

A composition comprising the isolated antibody or antigen binding fragment thereof of claim 36 and a pharmaceutically acceptable excipient, vehicle, or carrier.

### Claim 46 (depends on 44)

A method of producing an antibody or antigen binding fragment thereof, the method comprising culturing the host cell of claim 44 under conditions for production of the antibody or antigen binding fragment thereof.

### Claim 47 (depends on 46)

The method of claim 46, further comprising culturing host cells under conditions for production of said antibody or antigen binding fragment thereof.

### Claim 48 (depends on 47)

The method of claim 47, further comprising isolating and/or purifying said antibody or antigen binding fragment thereof.

### Claim 49

A method comprising contacting cells in the nervous system with an antibody comprises a heavy chain variable region comprising a heavy chain complementarity determining region (CDRH) 1 comprising GGSISSYF (SEQ ID NO: 20), a CDRH2 comprising IHYSGTT (SEQ ID NO: 22), a CDRH3 comprising ARGRGMATLPFDY (SEQ ID NO: 23) and a light chain variable region comprising a light chain complementarity determining region (CDRL) 1 comprising QSISSY (SEQ ID NO: 24), a CDRL2 comprising AAS (SEQ ID NO: 34), and a CDRL3 comprising QQSYSTPLT (SEQ ID NO: 40).

### Claim 50 (depends on 49)

The method of claim 49, wherein the cells in the nervous system are in the central nervous system (CNS).
